Clinical Trial Update: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial investigating CRLX101 in combination with enzalutamide for metastatic castration-resistant prostate cancer after prior enzalutamide exposure; tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Neoplasms

Drugs mentioned

• CRLX101
• Enzalutamide (enzalutamide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2022-07-12